Wearable Orthopedic Platform Commercialization Under Bundled Payment Risk

01 · Business Challenge

Bundled Risk Made Buyer Economics the Commercialization Problem

Buyers needed economic proof, clinical workflow fit and compelling proof to align internal financial, clinical, IT and procurement decision makers.

02 · Mandate

Prove the Business Case Before Advancing the Next Gate

Leadership needed enough economic, clinical and operating evidence to decide whether the platform should advance to the next commercialization gate before further investment or enterprise deployment.

03 · Work Addressed

Five Workstreams Connected Discovery to Executive Decision Gates

InteliGems led five workstreams.

04 · Accountable Review

Executive and Board Review Preserved Client Authority at Each Commercial Gate

Evidence did not convert into an automatic go decision. Executive team, CEO and board review governed whether the client advanced, refined, piloted or stopped, preserving client authority over each commitment.

SWIPE →

05 · Operating Insight

Clinical Evidence Needed a Physician Champion to Become a Buying Decision

Commercialization required more than evidence. The buyer needed a defensible economic case, stakeholders willing to operationalize the solution in clinical workflows, and an internal physician champion capable of carrying the decision across finance, clinical, IT, procurement and executive decision-makers.

OPERATING INSIGHT 01 · ECONOMIC ALIGNMENT

Align episode savings with practice-side economics.

The model paired hospital episode savings with practice-side value instead of assuming one stakeholder captured all value.

OPERATING INSIGHT 02 · DATA TO ACTION

Turn recovery data into assigned clinical action.

The operating design assigned review ownership, alert thresholds and coordinator response so monitoring produced accountable action.

06 · Evidence & Results

Buyer-Specific Economics Established the Value Case

The $1.86M modeled net impact was the Primary Proof. Achieved beta adherence and fewer postoperative PT visits supported the clinical thesis as separate evidence classes.

$1.86M

Modeled net impact

PRIMARY PROOF · MODELED · 350% NET ROI · 1,407 EPISODES

75–83%

Patient exercise adherence

SUPPORTING EVIDENCE · ACHIEVED CLINICAL BETA

−30%

Post-op PT visits

SUPPORTING EVIDENCE · ACHIEVED CLINICAL BETA

Performance indicator	Value	Evidence classification
Patient Home Exercise Program adherence	75–83% (vs. 20–40% control)	Achieved clinical beta
Post-op PT visit reduction	−30% (6 weeks to discharge vs. 8)	Achieved clinical beta
Discharge functional scores	+20–33% above benchmarks	Achieved clinical beta
Patient satisfaction	91%; 90%+ "very easy" usability	Achieved clinical beta
Pre-op protocol habituation	81–83% before surgery	Achieved clinical beta
Gross value created	$2,395,000 per 1,407 episodes	Modeled proforma
Net financial impact	$1,863,000 (350% net ROI)	Modeled proforma
CPT 97750 reimbursement	$33.90/unit; up to 4 units post-op = $135.60/patient	Regulatory reimbursement rule
Competitor pricing benchmark	$100–$200 per patient episode (HealthLoop, Force Therapeutics, Motion 360, CareSense)	Published market research
Published benchmark program SNF-to-home benchmark	−35% SNF discharges; $4,000/patient; 2% readmission	Published case benchmark
Accounts engaged across VOC and pipeline activity	25+ organizations with documented VOC and commercial progression activity	Documented pipeline progression
Enterprise account engagement chronology	~5 months: discovery → ROI → pilot discussion → live demo	Documented pipeline progression

07 · Commercial Execution in Practice

The Operating Mechanics & Care Path Flow That Realized the Value Case

How InteliGems connected physical therapy workflows, automated CPT 97750 testing reports into the EMR, and de-risked enterprise purchasing gates across 25+ health systems.

Historical market analysis was used to decide how the platform should compete, not simply how it compared feature by feature. The positioning logic connected objective recovery data to episode economics, practice-side value, workflow fit, and a lower-risk path to buyer evaluation.

2026 reimbursement and market examples are current context only and should not be read as historical client results.

HISTORICAL MARKET AUDIT

Digital Recovery Alternatives

The 2016 competitive work reviewed direct CJR platforms, wearable sensors, patient engagement tools, outcomes reporting products, and adjacent utilization management categories. Board pricing benchmarks included HealthLoop, Reflexion Health, Force Therapeutics, Motion 360, Sensoria, Notch, CareSense, and others.

STANDARD OF CARE

In-Person Physical Therapy

The status quo also competed for the buyer's budget. Traditional therapy carried substantial visit volume while home exercise adherence remained low. The commercial problem was to improve episode economics without weakening physician practice economics.

POSITIONING INSIGHT

The Competitive Shift Was From Sensor Features to an Economic Operating Model

Feature differentiation alone was not enough. The offer connected objective recovery data to episode savings, practice revenue, care team capacity, workflow integration, and a performance warranty that reduced buyer risk.

SWIPE →

Historical reimbursement logic

The 2016 to 2017 commercial model used CPT 97750 physical performance testing at the then documented Medicare baseline of $33.90 per 15 minute unit, including a separate benchmarking report requirement. The case should preserve that value as historical engagement evidence rather than present it as a current reimbursement quote.

2026 reimbursement context

CPT 97750 remains active, with a current national Medicare benchmark still near $34 per unit before locality and practitioner adjustments. Modern digital MSK programs also use Remote Therapeutic Monitoring for qualifying services. Approximate 2026 national non APM averages are 98975 at $21.71, 98985 and 98977 at $40.08, 98979 at $26.39, 98980 at $54.11, and 98981 at $41.42. CMS added 98985 and 98979 for 2026.

2026 market evolution

Force Therapeutics remains active in orthopedic episode management and RTM. Limber Health supports RTM-based MSK workflows. Hinge Health now spans prehab, surgery, and postoperative recovery. Sword Health acquired Kaia Health in 2026, while CareSense remains active in care navigation and outcomes reporting. These are current market examples, not historical engagement competitors.

Episode models make the insight more relevant

CMS TEAM is mandatory in selected markets from 2026 through 2030, and CJR-X is scheduled to begin nationwide in 2028 for lower extremity joint replacement. Reimbursement mechanisms have evolved, but the core commercialization problem remains: connect recovery technology to episode economics, workflow, evidence, and buyer risk.

Currency: prices and CPT 97750 values above are historical 2016 to 2017 data. Current reimbursement depends on CMS fee schedules, locality, payer coverage, medical necessity, documentation, and billing rules. Current market examples are included only to show category evolution.

08 · Executive Relevance

Advance Only When Economics and Clinical Operations Justify the Next Commercialization Step

01 · Economic Proof

Does the buyer-specific value case withstand local assumptions?

02 · Operating Ownership

Who acts on the evidence, and what changes in workflow?

03 · Decision Gate

Orthopedic Platform Under Bundled Payment Risk

Bundled Risk Made Buyer Economics the Commercialization Problem

Prove the Business Case Before Advancing the Next Gate

Five Workstreams Connected Discovery to Executive Decision Gates

Executive and Board Review Preserved Client Authority at Each Commercial Gate

Clinical Evidence Needed a Physician Champion to Become a Buying Decision

Align episode savings with practice-side economics.

Turn recovery data into assigned clinical action.

Buyer-Specific Economics Established the Value Case

Modeled net impact

Patient exercise adherence

Post-op PT visits

The Operating Mechanics & Care Path Flow That Realized the Value Case

Advance Only When Economics and Clinical Operations Justify the Next Commercialization Step

Does the buyer-specific value case withstand local assumptions?

Who acts on the evidence, and what changes in workflow?

Is the evidence sufficient to pilot, invest, scale, redesign or stop?

Bring the mandate

Advisory

Company

We value your privacy

Orthopedic Platform Under Bundled Payment Risk

Bundled Risk Made Buyer Economics the Commercialization Problem

Prove the Business Case Before Advancing the Next Gate

Five Workstreams Connected Discovery to Executive Decision Gates

Executive and Board Review Preserved Client Authority at Each Commercial Gate

Clinical Evidence Needed a Physician Champion to Become a Buying Decision

Align episode savings with practice-side economics.

Turn recovery data into assigned clinical action.

Buyer-Specific Economics Established the Value Case

Modeled net impact

Patient exercise adherence

Post-op PT visits

The Operating Mechanics & Care Path Flow That Realized the Value Case

Advance Only When Economics and Clinical Operations Justify the Next Commercialization Step

Does the buyer-specific value case withstand local assumptions?

Who acts on the evidence, and what changes in workflow?

Is the evidence sufficient to pilot, invest, scale, redesign or stop?

Related work

Pick the First Civilian Market Before More Capital and Filings

Rebuild a $1M License Case the CFO Could Test

Do Not Force One Digital Workflow on Every Clinical Role

Bring the mandate

Advisory

Company